{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:30:57Z","timestamp":1772166657157,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN-US-987-6016"],"award-info":[{"award-number":["IN-US-987-6016"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pilot Feasibility Stud"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatitis C virus (HCV) is the leading indication for liver transplantation and liver-related mortality. The development of direct-acting antivirals (DAA) and a simplified treatment algorithm with a\u2009&gt;\u200997% cure rate should make global elimination of HCV an achievable goal. Yet, vulnerable populations with high rates of HCV still have limited access to treatment. By designing locally contextualized site-specific HCV treatment workflows, we aim to cure HCV in vulnerable, high-risk populations, including people experiencing homelessness (PEH) and people who inject drugs (PWID), in Austin, TX, USA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Our implementation science study will utilize a qualitative and design thinking approach to characterize patient and systemic barriers and facilitators to HCV treatment in vulnerable, high-risk populations seeking care across seven diverse primary care clinics serving PEHs and PWIDs. Qualitative interviews guided by the Practical, Robust Implementation and Sustainability Model (PRISM) framework will identify barriers and facilitators by leveraging knowledge and experience from both clinic staff and patients. Data synthesized using thematic analysis and design thinking will feed into workshops with clinic stakeholders for idea generation to design site-specific HCV treatment workflows. Providers will be trained on the use of a simplified HCV treatment algorithm with DAAs and clinic staff on the new site-specific HCV treatment workflows. These workflows will be implemented by the seven diverse primary care clinics serving vulnerable, high-risk populations. Implementation and clinical outcomes will be measured using data collected through interviews with staff as well as through medical chart review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our study provides a model of how to contextualize and implement site-specific HCV treatment workflows targeting vulnerable, high-risk populations in other geographic locations. This model can be adopted for future implementation research programs aiming to develop and implement site-specific treatment workflows for vulnerable, high-risk populations and in primary care clinical settings for other disease states beyond just HCV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Registered on\n                      <jats:italic>ClinicalTrials.gov<\/jats:italic>\n                      on July, 14, 2022. Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05460130\">NCT05460130<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40814-023-01311-4","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T04:01:54Z","timestamp":1683518514000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Development, implementation, and feasibility of site-specific hepatitis C virus treatment workflows for treating vulnerable, high-risk populations: protocol of the Erase Hep C study \u2014 a prospective single-arm intervention trial"],"prefix":"10.1186","volume":"9","author":[{"given":"Anmol","family":"Desai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"O\u2019Neal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kia","family":"Reinis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristal","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Stefanowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darlene","family":"Bhavnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8831-0569","authenticated-orcid":false,"given":"Tim","family":"Mercer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"issue":"5 Suppl 3","key":"1311_CR1","first-page":"1","volume":"15","author":"DT Dieterich","year":"2019","unstructured":"Dieterich DT. A simplified algorithm for the management of hepatitis C infection. Gastroenterol Hepatol (N Y). 2019;15(5 Suppl 3):1\u201312.","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"7","key":"1311_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101554","volume":"9","author":"BR Yehia","year":"2014","unstructured":"Yehia BR, Schranz AJ, Umscheid CA, Lo RV. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS ONE. 2014;9(7): e101554.","journal-title":"PLoS ONE"},{"issue":"12","key":"1311_CR3","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","volume":"5","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192\u2013207.","journal-title":"Lancet Glob Health"},{"issue":"2","key":"1311_CR4","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1353\/hpu.2012.0047","volume":"23","author":"AJ Strehlow","year":"2012","unstructured":"Strehlow AJ, Robertson MJ, Zerger S, Rongey C, Arangua L, Farrell E, et al. Hepatitis C among clients of health care for the homeless primary care clinics. J Health Care Poor Underserved. 2012;23(2):811\u201333.","journal-title":"J Health Care Poor Underserved"},{"issue":"9","key":"1311_CR5","doi-asserted-by":"publisher","first-page":"594","DOI":"10.7326\/M18-1715","volume":"170","author":"MJ Akiyama","year":"2019","unstructured":"Akiyama MJ, Norton BL, Arnsten JH, Agyemang L, Heo M, Litwin AH. Intensive models of hepatitis C care for people who inject drugs receiving opioid agonist therapy: a randomized controlled trial. Ann Intern Med. 2019;170(9):594\u2013603.","journal-title":"Ann Intern Med"},{"issue":"7","key":"1311_CR6","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/cid\/ciz384","volume":"70","author":"S Gutkind","year":"2020","unstructured":"Gutkind S, Schackman BR, Morgan JR, Leff JA, Agyemang L, Murphy SM, et al. Cost-effectiveness of hepatitis C virus treatment models for people who inject drugs in opioid agonist treatment programs. Clin Infect Dis. 2020;70(7):1397\u2013405.","journal-title":"Clin Infect Dis"},{"issue":"23","key":"1311_CR7","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1056\/NEJMoa1009370","volume":"364","author":"S Arora","year":"2011","unstructured":"Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011;364(23):2199\u2013207.","journal-title":"N Engl J Med"},{"key":"1311_CR8","doi-asserted-by":"publisher","first-page":"8434602","DOI":"10.1155\/2019\/8434602","volume":"2019","author":"TA Syed","year":"2019","unstructured":"Syed TA, Bashir MH, Farooqui SM, Chen A, Chen S, Nusrat S, et al. Treatment outcomes of hepatitis C-infected patients in specialty clinic vs. primary care physician clinic: a comparative analysis. Gastroenterol Res Pract. 2019;2019:8434602.","journal-title":"Gastroenterol Res Pract."},{"issue":"6","key":"1311_CR9","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/jamainternmed.2017.0358","volume":"177","author":"JA Barocas","year":"2017","unstructured":"Barocas JA, Beiser M, Le\u00f3n C, Gaeta JM, O\u2019Connell JJ, Linas BP. Experience and outcomes of hepatitis C treatment in a cohort of homeless and marginally housed adults. JAMA Intern Med. 2017;177(6):880\u20132.","journal-title":"JAMA Intern Med"},{"key":"1311_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.drugpo.2019.03.017","volume":"72","author":"ME Beiser","year":"2019","unstructured":"Beiser ME, Smith K, Ingemi M, Mulligan E, Baggett TP. Hepatitis C treatment outcomes among homeless-experienced individuals at a community health centre in Boston. Int J Drug Policy. 2019;72:129\u201337.","journal-title":"Int J Drug Policy"},{"key":"1311_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.drugpo.2019.02.012","volume":"72","author":"BL Harney","year":"2019","unstructured":"Harney BL, Whitton B, Lim C, Paige E, McDonald B, Nolan S, et al. Quantitative evaluation of an integrated nurse model of care providing hepatitis C treatment to people attending homeless services in Melbourne. Australia Int J Drug Policy. 2019;72:195\u20138.","journal-title":"Australia Int J Drug Policy"},{"issue":"5","key":"1311_CR12","first-page":"685","volume":"64","author":"MM Ford","year":"2017","unstructured":"Ford MM, Johnson N, Desai P, Rude E, Laraque F. From care to cure: demonstrating a model of clinical patient navigation for hepatitis C care and treatment in high-need patients. Clin Infect Dis. 2017;64(5):685\u201391.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1311_CR13","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/hep4.1646","volume":"5","author":"AA Patel","year":"2021","unstructured":"Patel AA, Bui A, Prohl E, Bhattacharya D, Wang S, Branch AD, et al. Innovations in hepatitis C screening and treatment. Hepatol Commun. 2021;5(3):371\u201386.","journal-title":"Hepatol Commun"},{"key":"1311_CR14","doi-asserted-by":"publisher","unstructured":"Strebe J, Rich NE, Wang L, Singal AG, McBryde J, Silva M, et al. Patient navigation increases linkage to care and receipt of direct-acting antiviral therapy in patients with hepatitis C. Clin Gastroenterol Hepatol. 2023;21(4):988\u2013994.e2. https:\/\/doi.org\/10.1016\/j.cgh.2022.04.031. Epub 2022 May 14.","DOI":"10.1016\/j.cgh.2022.04.031"},{"issue":"8","key":"1311_CR15","doi-asserted-by":"publisher","first-page":"ofac350","DOI":"10.1093\/ofid\/ofac350","volume":"9","author":"T Papaluca","year":"2022","unstructured":"Papaluca T, Craigie A, McDonald L, Edwards A, Winter R, Hoang A, et al. Care navigation increases initiation of hepatitis C treatment after release from prison in a prospective randomized controlled trial: the C-LINK Study. Open Forum Infect Dis. 2022;9(8):ofac350.","journal-title":"Open Forum Infect Dis."},{"issue":"12","key":"1311_CR16","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/S2468-1253(22)00275-8","volume":"7","author":"AH Litwin","year":"2022","unstructured":"Litwin AH, Lum PJ, Taylor LE, Mehta SH, Tsui JI, Feinberg J, et al. Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial. Lancet Gastroenterol Hepatol. 2022;7(12):1112\u201327.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1311_CR17","doi-asserted-by":"publisher","unstructured":"Pearson N, Naylor P-J, Ashe MC, Fernandez M, Yoong SL, Wolfenden L. Guidance for conducting feasibility and pilot studies for implementation trials.\u00a0Pilot Feasibility Stud. 2020;6(1):167. https:\/\/doi.org\/10.1186\/s40814-020-00634-w.","DOI":"10.1186\/s40814-020-00634-w"},{"issue":"4","key":"1311_CR18","first-page":"228","volume":"34","author":"AC Feldstein","year":"2008","unstructured":"Feldstein AC, Glasgow RE. A practical, robust implementation and sustainability model (PRISM) for integrating research findings into practice. Jt Comm J Qual Patient Saf. 2008;34(4):228\u201343.","journal-title":"Jt Comm J Qual Patient Saf"},{"issue":"9","key":"1311_CR19","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.2105\/AJPH.89.9.1322","volume":"89","author":"RE Glasgow","year":"1999","unstructured":"Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89(9):1322\u20137.","journal-title":"Am J Public Health"},{"issue":"1","key":"1311_CR20","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1186\/s12913-021-06930-2","volume":"21","author":"MKM Pillsbury","year":"2021","unstructured":"Pillsbury MKM, Mwangi E, Andesia J, Njuguna B, Bloomfield GS, Chepchumba A, et al. Human-centered implementation research: a new approach to develop and evaluate implementation strategies for strengthening referral networks for hypertension in western Kenya. BMC Health Serv Res. 2021;21(1):910.","journal-title":"BMC Health Serv Res"},{"key":"1311_CR21","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/joim.12740","volume":"283","author":"S Olafsson","year":"2018","unstructured":"Olafsson S, Tyrfingsson T, Runarsdottir V, Bergmann O, Hansdottir I, Bj\u00f6rnsson E, et al. Treatment as prevention for hepatitis C (TraP Hep C) \u2013 a nationwide elimination programme in Iceland using direct-acting antiviral agents. J Intern Med. 2018;283:500\u20137.","journal-title":"J Intern Med"},{"key":"1311_CR22","unstructured":"(UCSF) University of California San Fransisco. Gastrointestinal & hepatobiliary consultation service: UCSF Departments of Pathology and Laboratory Medicine; 2023. Available from: https:\/\/pathology.ucsf.edu\/consultation-services\/gi-hep."},{"issue":"3","key":"1311_CR23","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1002\/hep.23802","volume":"52","author":"S Arora","year":"2010","unstructured":"Arora S, Kalishman S, Thornton K, Dion D, Murata G, Deming P, et al. Expanding access to hepatitis C virus treatment\u2013Extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care. Hepatology. 2010;52(3):1124\u201333.","journal-title":"Hepatology"}],"updated-by":[{"DOI":"10.1186\/s40814-023-01347-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000}}],"container-title":["Pilot and Feasibility Studies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40814-023-01311-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40814-023-01311-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40814-023-01311-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T02:07:30Z","timestamp":1688090850000},"score":1,"resource":{"primary":{"URL":"https:\/\/pilotfeasibilitystudies.biomedcentral.com\/articles\/10.1186\/s40814-023-01311-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,8]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1311"],"URL":"https:\/\/doi.org\/10.1186\/s40814-023-01311-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2399039\/v1","asserted-by":"object"}]},"ISSN":["2055-5784"],"issn-type":[{"value":"2055-5784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,8]]},"assertion":[{"value":"21 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s40814-023-01347-6","URL":"https:\/\/doi.org\/10.1186\/s40814-023-01347-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Erase Hep C study was approved by the University of Texas at Austin\u2019s Institutional Review Board (IRB), as well as CommUnityCare\u2019s Research and Quality Improvement Committee. This protocol was submitted in two parts to the IRB. Any significant protocol amendments of how site-specific HCV treatment workflows are implemented will be submitted as modifications to the IRB and updated on ClinicalTrials.gov. Written voluntary informed consent will be obtained from potential study participants for the baseline qualitative interviews and at the time of enrollment into the trial by the research coordinator or research assistant. We also obtained a Certificate of Confidentiality from the National Institutes of Health (NIH) for all study participants.We do not anticipate any serious adverse events. We expect any adverse events or harms to study participation to be related to risk of data breach or risk of uncomfortableness and inconvenience of time. For data and safety monitoring, any data breaches and any such social harms will be reported to the UT IRB. The participants\u2019 safety will be monitored by the clinic, as per the standard of care.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}